Revolution Medicines (RVMD) Liabilities and Shareholders Equity (2019 - 2026)

Revolution Medicines' Liabilities and Shareholders Equity history runs 8 years deep, the most recent figure standing at $2.3 billion for Q1 2026.

• On a quarterly basis, Liabilities and Shareholders Equity fell 4.72% year-over-year to $2.3 billion in Q1 2026; TTM through Mar 2026 was $9.3 billion, a 37.78% increase from a year earlier, with the FY2025 full-year figure at $2.4 billion, down 7.97% from the prior year.
• Liabilities and Shareholders Equity slipped to $2.3 billion in Q1 2026 per RVMD's latest filing, from $2.4 billion in the prior quarter.
• Across five years, Liabilities and Shareholders Equity topped out at $2.6 billion in Q4 2024 and bottomed at $55.9 million in Q2 2024.
• The 5-year median for Liabilities and Shareholders Equity is $1.8 billion (2024), against an average of $1.5 billion.
• Across the five-year window, Liabilities and Shareholders Equity sank 94.79% in 2024 and jumped 4246.28% in 2025, its largest moves.
• Year by year, Liabilities and Shareholders Equity stood at $811.9 million in 2022, then jumped by 153.93% to $2.1 billion in 2023, then climbed by 24.09% to $2.6 billion in 2024, then decreased by 7.97% to $2.4 billion in 2025, then dropped by 4.28% to $2.3 billion in 2026.
• Per Business Quant, the three latest RVMD Liabilities and Shareholders Equity figures stand at $2.3 billion (Q1 2026), $2.4 billion (Q4 2025), and $2.3 billion (Q3 2025).